Department of Orthopedics, University of Colorado School of Medicine, Aurora, CO, 80045, USA.
Department of Orthopedics, Seton Hall-Hackensack Meridian School of Medicine, South Orange, NJ, 07079, USA.
Knee Surg Sports Traumatol Arthrosc. 2018 Aug;26(8):2259-2269. doi: 10.1007/s00167-018-4838-1. Epub 2018 Jan 16.
The purpose of this systematic review is to evaluate the current literature in an effort to assess specific clinical outcomes following meniscal scaffold implantation using the two available scaffolds: Collagen Meniscal Implant (CMI) and the Actifit polyurethane meniscal scaffold.
A systematic review was performed by searching PubMed, Embase, and Cochrane Library to find studies evaluating clinical outcomes of patients undergoing meniscal scaffold implantation. Search terms used were "meniscus", "meniscal", "scaffold", and "implant". Studies were evaluated based on scaffold type, treatment failure rates, patient-reported outcome scores, concomitant procedures, and radiological findings. Radiological findings were recorded using the Genovese scale to assess morphology and signal intensity and the Yulish score to assess articular cartilage.
Nineteen studies (1 level I, 1 level II, 17 level IV evidence) were identified that met inclusion criteria, including a total of 658 patients (347 Actifit, 311 CMI). The overall average follow-up was 45 months. Treatment failure occurred in 9.9% of patients receiving the Actifit scaffold at a mean follow-up of 40 months and 6.7% of patients receiving CMI at a mean follow-up of 44 months (n.s.). However, the rate of failure ranged from 0 to 31.8% amongst the included studies with a variable definition of failure. Additionally, overlapping patients and presence of concomitant surgeries such as anterior cruciate ligament reconstruction (ACLR) and high tibial osteotomy (HTO) may have a significant influence on these results. Outcomes for the Visual Analog Scale (VAS) for pain, Lysholm knee score, and Tegner activity score improved from preoperatively to latest follow-up in both groups, while the Knee Injury and Osteoarthritis Outcome Score and International Knee Documentation Committee scores improved from preoperatively to latest follow-up for Actifit scaffold patients. Overall, patients receiving CMI scaffolds had higher grades for Genovese morphology and signal intensity when compared to Actifit scaffold patients.
Patients undergoing meniscal scaffold implantation with either CMI or Actifit scaffold can both be expected to experience improvement in clinical outcomes when used in association with concomitant procedures such as ACLR and HTO.
IV, systematic review.
本系统评价旨在评估当前文献,以评估使用两种现有支架(胶原半月板植入物[CMI]和 Actifit 聚氨酯半月板支架)进行半月板支架植入后的特定临床结果。
通过搜索 PubMed、Embase 和 Cochrane 图书馆,对评估半月板支架植入患者临床结果的研究进行了系统评价。使用的检索词为“半月板”、“半月板”、“支架”和“植入物”。研究基于支架类型、治疗失败率、患者报告的结果评分、伴随手术和影像学发现进行评估。使用 Genovese 量表评估形态和信号强度,使用 Yulish 评分评估关节软骨,记录影像学发现。
确定了 19 项符合纳入标准的研究(1 项 I 级,1 项 II 级,17 项 IV 级证据),共纳入 658 例患者(347 例 Actifit,311 例 CMI)。总体平均随访时间为 45 个月。在平均随访 40 个月时,接受 Actifit 支架治疗的患者中有 9.9%发生治疗失败,在平均随访 44 个月时,接受 CMI 治疗的患者中有 6.7%发生治疗失败(无统计学差异)。然而,在纳入的研究中,失败率从 0 到 31.8%不等,失败的定义也各不相同。此外,重叠患者和同时进行的手术(如前交叉韧带重建[ACLR]和高位胫骨截骨术[HTO])可能对这些结果有重大影响。两组患者的视觉模拟评分(VAS)疼痛评分、Lysholm 膝关节评分和 Tegner 活动评分均从术前改善至末次随访,而 Actifit 支架患者的膝关节损伤和骨关节炎结果评分和国际膝关节文献委员会评分从术前改善至末次随访。总体而言,与接受 Actifit 支架治疗的患者相比,接受 CMI 支架治疗的患者的 Genovese 形态和信号强度评分更高。
接受 CMI 或 Actifit 支架半月板支架植入的患者,在与 ACLR 和 HTO 等伴随手术联合使用时,均有望改善临床结果。
IV,系统评价。